Kura Oncology, INC Form 4 insider transactions

Thomas Doyle, SVP of Finance & Accounting at Kura Oncology, reports the acquisition of common stock and stock options, along with adjustments to his holdings, as per a recent SEC Form 4 filing.

Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, reports the acquisition of restricted stock units and options in Kura Oncology.

Brian Powl, Chief Commercial Officer of Kura Oncology, reports the acquisition of restricted stock units and options, as well as the disposal of common stock.

Kathleen Ford, Chief Operating Officer of Kura Oncology, reports the acquisition of stock options.

Troy Edward Wilson, President and CEO of Kura Oncology, Inc., was granted options to purchase 625,000 shares of common stock on January 2, 2025.

Kura Oncology's Chief Operating Officer, Kathleen Ford, acquired 526 shares of common stock through the company's Employee Stock Purchase Plan.

Michael Vasconcelles, a director at Kura Oncology, acquired options to purchase common stock in the company on September 13, 2024.

Mary T. Szela, a director of Kura Oncology, acquired options to purchase 26,000 shares of common stock on June 5, 2024.

Diane L. Parks, a director at Kura Oncology, acquired 26,000 stock options on June 5, 2024, exercisable for common stock.

Director Carol Schafer acquired options to purchase 26,000 shares of Kura Oncology stock on June 5, 2024.

Director Thomas Malley acquired options to purchase 26,000 shares of Kura Oncology stock on June 5, 2024.

Director Faheem Hasnain of Kura Oncology, Inc. acquired 26,000 stock options on June 5, 2024, according to a Form 4 filing with the SEC.

Director Helen Collins reports acquisition of 26,000 stock options in Kura Oncology, Inc.

Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, reports a sale of 2,615 shares and an acquisition of 2,615 shares of common stock on May 20, 2024.